



**3<sup>rd</sup> International  
Workshop on  
Liver & Gut  
Fibrosis**

16-17 OCTOBER 2025  
VALENCIA, SPAIN

## PROGRAMME

### THURSDAY 16TH OCTOBER 2025

8:30 - 9:00 am Registration

9:00 am Welcome & overview of the workshop

#### 9:15 - 10:30 am FIBROSIS: STATE-OF-THE-ART

Chairs: Ana Gutiérrez-Casbas and Rubén Francés

9:15 - 9:50 am *Intestinal fibrosis. Michael Scharl (University Hospital Zürich)*

9:50 - 10:25 am *Targeting the gut-liver axis using Yaq001 to prevent occurrence and progression of cirrhosis. Rajiv Jalan (University College London)*

10:30 - 11:00 am Coffee break

#### 11:00 am - 12:30 pm METABOLIC NETWORKS AND PLASTICITY IN FIBROSIS

Chairs: Ana Blas-García and Javier Cubero

11:00 - 11:20 am *Metabolic shifts in hepatic stellate cells: impacts on liver fibrosis. Rubén Nogueiras (Universidad de Santiago de Compostela)*

11:20 - 11:40 am *Microbiota and gut-liver axis in obesity. Yolanda Sanz (IATA, Valencia)*

11:40 am - 12:00 pm *Molecular mechanisms regulating cellular plasticity in liver fibrosis. Kim Ravnskjær (University of Southern Denmark)*

12:00 - 12:20 pm *Epithelial and endothelial plasticity in intestinal fibrosis. Sara Lovisa (Humanitas Research Hospital, Milan)*

12:20 - 12:30 pm General discussion

#### 12:30 - 1:30 pm ORAL PRESENTATIONS

Chairs: Rocío Gallego-Durán and María Dolores Barrachina

12:30 - 12:40 pm *Blockade of Platelet Activating Factor Receptor pathway with ligand antagonist BN-52021 reduces liver damage and proinflammatory gene expression in fibrotic mice. Oriol Juanola (Universidad Miguel Hernández, Alicante)*

12:40 - 12:50 pm *TWEAK-induced memory in intestinal fibroblasts is associated with epigenetic reprogramming in IBD-susceptibility genes. Cristina Bauset (University College Dublin)*

12:50 - 1:00 pm *A microfluidic human liver slice model for drug screening: GLP1-R agonist Liraglutide demonstrates antifibrotic activity. María Andrés (Barcelona Liver Bioservices)*

1:00 - 1:10 pm *Protective role of TPL2/MAP3K8 in hepatic stellate cells (HSC) during liver fibrosis. Sara García (Complutense University, Madrid)*

1:10 - 1:20 pm *Therapeutic effects of decanoic acid in acute and chronic murine models of colitis. Andrea Cejudo-Garcés (University of Valencia)*

1:20 - 1:30 pm *Integrative multi-omics of ballooned hepatocytes in MASH defines a diagnostic histopathological signature. Seray Anak (KU Leuven)*

1:30 - 3:00 pm Lunch

#### 3:00 - 4:35 pm ROLE OF THE IMMUNE RESPONSE-INTERACTOME IN FIBROSIS

Chairs: Frank Tacke and Mario Manresa

3:00 - 3:20 pm *Immunomodulatory function of intestinal fibroblasts in cirrhosis. Esther Caparrós (Universidad Miguel Hernández, Elche)*

3:20 - 3:40 pm *Understanding macrophage diversity and dysfunction in Crohn's disease. Calum Bain (University of Edinburgh)*

**3:40 - 4:00 pm** *Targeting the gut-liver axis in cirrhosis - an update from the clinical perspective.* **Benedikt Simbrunner (Medical University of Vienna)**

**4:00 - 4:20 pm** *Interaction between stromal and myeloid cells drives tissue remodeling in IBD.* **Gianluca Matteoli (KU Leuven)**

**4:20 - 4:35 pm** General discussion

**4:35 - 5:05 pm BASIC SCIENCE: STATE-OF-THE-ART**

Chairs: Jordi Gracia-Sancho and Sara Calatayud

*Cellular senescence: search and destroy.* **Manuel Collado (Universidad de Santiago de Compostela)**

**5:05 - 5:35 pm** Coffee break & Poster session

**5:35 - 6:35 pm ORAL PRESENTATIONS**

Chairs: Anabel Fernández Iglesias and Jesús Cosín

**5:35 - 5:45 pm** *Pressure-induced endothelial fibulin7 modulates HSC phenotype and lowers portal pressure in experimental cirrhosis.* **Raül Pastó (IDIBAPS, Barcelona)**

**5:45 - 5:55 pm** *The TNF superfamily factor TWEAK promotes inflammatory stroma-monocyte crosstalk in ulcerative colitis via heterologous NF- $\kappa$ B/STAT3 signalling.* **Carlos Matellan (University College Dublin)**

**5:55 - 6:05 pm** *Combined effect of Atorvastatin and Ambrisentan on the hemodynamic alterations and liver fibrosis in a translational rat model of MASLD with advanced fibrosis.* **María de la Serra (Vall d'Hebron Research Institute, Barcelona)**

**6:05 - 6:15 pm** *Targeted anti-MCL1 delivery in senescent cells reduces murine intestinal fibrosis.* **Ana Crespo (University of Valencia)**

**6:15 - 6:25 pm** *Dysregulation of the urea cycle enzymes determines a more severe MASLD phenotype in a DIAMOND preclinical model.* **Carola Zurita (Instituto de Biomedicina de Sevilla)**

**6:25 - 6:35 pm** *Cardiac fibroblast activation is induced by several integrase inhibitors in vitro.* **Víctor Collado-Díaz (University of Valencia)**

**8:30 pm** Drinks and canapés. Ateneo Mercantil (Sexta Planta)

**FRIDAY 17TH OCTOBER 2025**

**9:00 - 11:00 am MORBIDITY AND MORTALITY IN FIBROSIS**

Chairs: Juan Manuel Pericàs and Yamile Zabana

**9:00 - 9:25 am** *Fibrosis in IBD.* **Elena Ricart (Hospital Clínic Barcelona)**

**9:25 - 9:50 am** *Fibrosis and liver cancer.* **Beatriz Mínguez (Hospital Universitari Vall d'Hebron, Barcelona)**

**9:50 - 10:15 am** *Extracellular matrix molecules as biomarkers of gut fibrosis.* **Anja Poulsen (Rigshospitalet, Copenhagen)**

**10:15 - 10:40 am** *Clinical trials in liver fibrosis: an update.* **Frank Tacke (Charité – Universitätsmedizin Berlin)**

**10:40 - 11:00 am** General discussion

**11:00 am - 12:00 pm** Coffee break & Poster session

**12:00 - 1:45 pm DRUG DEVELOPMENT IN FIBROSIS**

Chairs: Sara Calatayud and Nadezda Apostolova

**12:00 - 12:25 pm** *Novel in vitro models to study anti-fibrotic drugs.* **Luca Urbani (Roger Williams Institute of Hepatology, London)**

**12:25 - 12:50 pm** *Targeting cellular mechanobiology to address fibrosis in cancer.* **Stephen Thorpe (University College Dublin)**

**12:50 - 1:15 pm** *Proteolytic enzymes driving macrophage phenotypical shift during fibrotic diseases.* **Anna Moles (IDIBAPS, Barcelona)**

**1:40 - 1:50 pm** *JAK-STAT pathway targeting as a treatment for inflammatory bowel disease.* **Mark Lowenberg (Amsterdam UMC)**

**1:40 - 1:50 pm** General discussion

**1:50 - 2:00 pm** Best Communication Award (sponsored by Biomolecules), Travel Grants (sponsored by PharmaNest) and concluding remarks